GLP-1 受体激动剂治疗患者的胆石症：随机对照试验的更新荟萃分析。
Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
机构信息
Diabetology, Careggi Hospital and University of Florence, Italy.
Diabetology, Careggi Hospital and University of Florence, Italy.
出版信息
Diabetes Res Clin Pract. 2020 Mar;161:108087. doi: 10.1016/j.diabres.2020.108087. Epub 2020 Feb 19.
Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).
胰高血糖素样肽-1 受体激动剂 (GLP1-RA) 在前一次荟萃分析中与胆石症相关。新试验的发表表明需要更新。我们收集了 GLP1-RA 与其他疗法的试验，计算了 Mantel-Haenszel 优势比 (MH-OR，95%CI)。GLP1-RA 显著增加了胆石症的风险 (MH-OR 1.28 [1.11, 1.48])。
Zotero 插件